Progress Announcement on Change of Company Control, Issuance of Shares for Asset Acquisition, and Related Transactions

Guilin Rhine Biotechnology Co., Ltd.
Securities Code: 002166
Securities Abbreviation: Rhine Biotechnology
Announcement No.: 2026-003

Guilin Rhine Biotechnology Co., Ltd. Progress Announcement on Change of Company Control, Issuance of Shares for Asset Acquisition, and Related Transactions

The company and all members of the board guarantee that the content of this information disclosure is true, accurate, and complete, without false records, misleading statements, or significant omissions.

Special Reminder:

1. Guilin Rhine Biotechnology Co., Ltd. (hereinafter referred to as "the Company") disclosed on December 24, 2025, the announcement titled "Announcement on the Signing of the 'Change of Control Framework Agreement,' 'Share Transfer Agreement,' 'Voting Rights Waiver Agreement,' 'Non-Control Commitment Letter' by the Controlling Shareholder and the Company's Signing of the 'Share Issuance Agreement for Asset Acquisition,' 'Conditional Share Subscription Agreement,' 'Equity Transfer Agreement,' and the Proposed Change of Control" (Announcement No.: 2025-076), as well as the "Plan for Issuing Shares to Acquire Assets and Raise Supporting Funds and Related Transactions" (hereinafter referred to as "the Transaction Plan") and its summary. The aforementioned disclosure documents detailed the risk factors and approval procedures related to the change of control, issuance of shares for asset acquisition, and fundraising (collectively referred to as "this transaction"). Investors are advised to pay attention to investment risks.
2. Since the disclosure of this transaction, the Company and relevant parties have actively promoted the share transfer agreements involved in this transaction, including due diligence, auditing, and valuation of the target company. As of the date of this announcement, the aforementioned work is progressing in an orderly manner as planned. The Company will convene the board of directors again to review the relevant matters of this transaction after all related work is completed and will fulfill subsequent approval procedures and information disclosure obligations in accordance with laws and regulations.